ClinicalTrials.gg
TerminatedNCT04368039Updated Oct 16, 2026

Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis

An interventional study of Normobaric Oxygen and Placebo in Psychosis, Schizophrenia and First-episode Psychosis, sponsored by Nicholas Breitborde. Terminated at 1 site in United States. Open to participants aged 15 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Nicholas Breitborde · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Vendor unable to continue to provide oxygen concentrators

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Dec 2019, registered Apr 2020).
Updated Oct 16, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
15 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 759 studies in Psychotic Disorders with a site in United States — 97 open to participants now, 113 under way, 7 of them phase 3. Psychotic Disorders · United States.

Enrollment
659th of 682
3 · median 60
Started
2019
with 41 others
No phase
338 of 759
57 open now
Registered
581st of 759
by date

Among the 759 studies in Psychotic Disorders with a site in United States, this one is the 659th largest by enrollment of the 682 interventional ones that give a count, is one of 42 that started in 2019, is one of 338 with no phase, and was the 581st registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

97 of the 759 studies in Psychotic Disorders with a site in United States are open now. Recruiting first, the newest first:

92 more — sign in →

All 97 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 15 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 759 studies in Psychotic Disorders with a site in United States, or all of them as a file.
02

Study summary

Single-blind, randomized controlled trial of normobaric oxygen therapy among individuals with first-episode psychosis: Effects on symptomatology and cognition.

Read the detailed description

Functional deficits in prefrontal, limbic, and temporal regions of the brain are well-documented among individuals with psychotic disorders. Mitochondrial dysfunction may contribute to such pathology, and effective functioning of mitochondrial activity in the brain in dependent on a sufficient supply of oxygen. These data suggest that oxygen therapy may improve symptoms in individuals with psychosis. This small pilot study will test this hypothesis.

Individuals with first-episode psychosis will be randomized to receive either (i) 4 weeks of nightly normobaric oxygen therapy (40% FiO2) or (ii) 4 weeks of a placebo condition utilizing room air oxygen levels (21% FiO2). Participants will be blinded to what condition they receive. Both conditions will be delivered via nasal cannula connected to oxygen concentrators at five liters per minute (lpm), and participants will be instructed to complete the intervention overnight while sleeping. At the end of the 4 week period, all individuals will receive an additional 4 weeks of unblinded (i.e., "open label") nightly normobaric oxygen therapy (40% FiO2). Study assessments will be completed at (i) enrollment; (ii) 4 weeks after enrollment, and (iii) 8 weeks after enrollment.

03

Conditions studied

  • Psychosis
  • Schizophrenia
  • First-episode Psychosis

Keywords

  • psychosis
  • treatment
  • normobaric hyperoxia
04

Who can participate

Ages eligible
15 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • Diagnosis of a schizophrenia-spectrum disorder or mood disorder with psychotic features as determined using the Structured Clinical Interview for the .
  • Less than 5 years since the onset of frank psychotic symptoms as determined using the Symptom Onset in Schizophrenia Inventory .
  • No evidence of a pre-existing intellectual disability defined as a premorbid IQ >70 as estimated using the Reading subtest of the Wide Range Achievement Test-4.
  • Ages 15-35
  • Non-smoker for past six months
  • Absence of suicidal ideation or behavior over the past month as assessed by the Columbia Suicide Severity Rating Scale
  • The American Association for Respiratory Care notes that "no absolute to oxygen therapy exist when indications [for oxygen therapy] are present."
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Normobaric Oxygen Therapy (40% FiO2)

    4 weeks of nightly normobaric oxygen therapy (40% FiO2)

    Device: Normobaric Oxygen

  • Placebo comparator
    Placebo Condition

    4 weeks of a placebo condition utilizing room air oxygen levels (21% FiO2)

    Device: Placebo

Interventions

  • DeviceNormobaric Oxygen

    40% FiO2 for 4 weeks

  • DevicePlacebo

    21% FiO2 for 4 weeks

06

What researchers measure

Primary outcomes

  1. Change from baseline in cognitive functioning

    Change in scores on the MATRICS Consensus Cognitive Battery (MCCB).

    Time frame: 4 weeks

  2. Change from baseline in quality of life

    Change in scores on WHO Quality of Life Scale Brief (WHOQOL-BREF.

    Time frame: 4 weeks

  3. Change from baseline in social functioning

    Change in scores on the Global Functioning: Social Scale. Scores on this measure range from 1-10 with higher scores indicating greater social functioning

    Time frame: 4 weeks

  4. Change from baseline in role functioning

    Change in scores on the Global Functioning: Role Scale. Scores on this measure range from 1-10 with higher scores indicative of greater role functioning.

    Time frame: 4 weeks

  5. Change from baseline in health-related quality of life

    Change in scores on the RAND 36-Item Health Survey.

    Time frame: 4 weeks

Secondary outcomes

  1. Change from baseline in suicidality

    Change in occurrence in suicidal thoughts or behaviors as assessed using the Columbia Suicide Severity Rating Scale. This is a categorical rating scale that identifies the presence or absence of specific levels of severity of suicidal ideation and behavior.

    Time frame: 4 weeks

  2. Change from baseline in substance use severity

    Change in scores on the HABITS scale. This scale assesses the absolute values of use of specific substances (e.g., number of cigarettes smoked)

    Time frame: 4 weeks

  3. Change from baseline in service utilization

    Change in scores on the Modified Service Use and Resources Form for Schizophrenia

    Time frame: 4 weeks

  4. Change in Sleep

    Change in scores on the Pittsburgh Sleep Quality Index.

    Time frame: 4 weeks

  5. Change from baseline in medication adherence

    Change in scores on the Medication Adherence rating Scale. Scores on this scale range from 0-10 with higher scores indicative of greater medication adherence.

    Time frame: 4 weeks

07

Study locations

1 site
  • Harding Hospital
    Columbus, Ohio 43210, United States
08

References and documents

Publications

  • Hill K, Mann L, Laws KR, Stephenson CM, Nimmo-Smith I, McKenna PJ. Hypofrontality in schizophrenia: a meta-analysis of functional imaging studies. Acta Psychiatr Scand. 2004 Oct;110(4):243-56. doi: 10.1111/j.1600-0447.2004.00376.x. PubMed 15352925 ↗
  • Karry R, Klein E, Ben Shachar D. Mitochondrial complex I subunits expression is altered in schizophrenia: a postmortem study. Biol Psychiatry. 2004 Apr 1;55(7):676-84. doi: 10.1016/j.biopsych.2003.12.012. PubMed 15038995 ↗
  • Kann O, Kovacs R. Mitochondria and neuronal activity. Am J Physiol Cell Physiol. 2007 Feb;292(2):C641-57. doi: 10.1152/ajpcell.00222.2006. Epub 2006 Nov 8. PubMed 17092996 ↗
  • Bloch Y, Applebaum J, Osher Y, Amar S, Azab AN, Agam G, Belmaker RH, Bersudsky Y. Normobaric hyperoxia treatment of schizophrenia. J Clin Psychopharmacol. 2012 Aug;32(4):525-30. doi: 10.1097/JCP.0b013e31825d70b8. PubMed 22722511 ↗
  • First, M.B., et al., Structured Clinical Interview for DSM-5-Research Version2015, Arlington, VA: American Psychiatric Association.
  • Perkins DO, Leserman J, Jarskog LF, Graham K, Kazmer J, Lieberman JA. Characterizing and dating the onset of symptoms in psychotic illness: the Symptom Onset in Schizophrenia (SOS) inventory. Schizophr Res. 2000 Jul 7;44(1):1-10. doi: 10.1016/s0920-9964(99)00161-9. PubMed 10867307 ↗
  • Wilkinson, G.S. and G.J. Robertson, Wide Range Achievement Test (WRAT4)2006, Lutz, FL: PAR, Inc.
  • Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011 Dec;168(12):1266-77. doi: 10.1176/appi.ajp.2011.10111704. PubMed 22193671 ↗
  • AARC. AARC clinical practice guideline. Oxygen therapy in the home or alternate site health care facility--2007 revision & update. Respir Care. 2007 Aug;52(8):1063-8. No abstract available. PubMed 17715561 ↗
  • Schizophrenia Spectrum and Other Psychotic Disorders, in DSM-5® Clinical Cases.
  • Auther, A., C. Smith, and B. Cornblatt, Global Functioning: Social Scale (GF: Social). Glen Oaks, NY: Zucker-Hillside Hospital, 2006.
  • Niendam, T., et al., Global Functioning: Role Scale (GF: Role). Los Angeles, CA: University of California, Los Angeles, 2006.
  • Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J; CATIE Study Investigators. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry. 2006 Dec;163(12):2080-9. doi: 10.1176/ajp.2006.163.12.2080. PubMed 17151158 ↗
  • Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ 3rd, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008 Feb;165(2):203-13. doi: 10.1176/appi.ajp.2007.07010042. Epub 2008 Jan 2. PubMed 18172019 ↗
  • Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group. Psychol Med. 1998 May;28(3):551-8. doi: 10.1017/s0033291798006667. PubMed 9626712 ↗
  • Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000 May 5;42(3):241-7. doi: 10.1016/s0920-9964(99)00130-9. PubMed 10785582 ↗
  • Hays, R.D., S. Prince-Embury, and H.Y. Chen, RAND-36 Health Status Inventory1998, San Antonio, TX: The Psychological Corporation.
  • Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull. 1986;22(2):343-81. No abstract available. PubMed 3774930 ↗
  • Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4. PubMed 2748771 ↗
  • Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005 Mar;62(3):247-53. doi: 10.1001/archpsyc.62.3.247. PubMed 15753237 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Dec 2019 to primary completion in Oct 2026, 82 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Dec 2026 → Oct 2026 and completion Dec 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2020
First posted
Apr 29, 2020
StartActual
Dec 4, 2019
Primary completionActual
Oct 13, 2026was Dec 2026
CompletionActual
Oct 13, 2026was Dec 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Vendor unable to continue to provide oxygen concentrators
changed Oct 16, 2026
Primary completion
Dec 7, 2026→Oct 13, 2026 (actual)
Oct 16, 2026
Study completion
Dec 7, 2026→Oct 13, 2026 (actual)
Oct 16, 2026
Enrollment
20 (estimated)→3 (actual)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Recruiting→Terminated
    Why stopped Vendor unable to continue to provide oxygen concentrators
    Primary completion Dec 7, 2026→Oct 13, 2026 (now actual)
    Study completion Dec 7, 2026→Oct 13, 2026 (now actual)
    Enrollment 20 (estimated)→3 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04368039
Lead sponsor
Nicholas Breitborde
Responsible party
Nicholas Breitborde (Principal Investigator, Ohio State University) — Sponsor-investigator
First posted
Apr 29, 2020
Start date
Dec 4, 2019
Primary completion
Oct 13, 2026
Completion
Oct 13, 2026
Last update
Oct 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion